Replies to post #44087 on Ethema Health Corp (GRST)

[Bubae]

I don't see where I have been wrong concerning debt dilution and the direction of the price for the past year. We will see something soon I believe. The last time that they were on pace for this kind of professional services spend was in 2020 when they were working the deal to purchase their share of ARIA and the massive debt restructuring detailed in the 31 documents of the December 2020 8K. I believe a lot is going on behind the scenes and no one holding shares of the common will like it.



For the fiscal year ended: December 31, 2021
https://sec.report/Document/0001903596-22-000192/

Professional fees were $132,275 and $231,264 for the years ended December 31, 2021 and 2020, respectively,a decrease of $98,989 or 42.8%. The decrease is primarily due to consulting fees that were paid to two individuals in the prior year who had assisted with business development efforts.


For the quarterly period ended March 31, 2022
https://sec.report/Document/0001903596-22-000301/

Q1 2022 Professional fees $49,587

For the quarterly period ended June 30, 2022
https://sec.report/Document/0001903596-22-000529/

Q2 2022 Professional fees $112,149

Total for the first 6 months of 2022 $161, 736


Debt restructuring 8K December 2020
https://sec.report/Document/0001721868-20-000600/

Exhibit No. Description
10.01 Securities Purchase Agreement dated October 29, 2020 (FirstFire SPA)
10.02 Convertible Promissory Note dated October 29, 2020 (FirstFire Note)
10.03 Option Agreement dated October 29, 2020 (FirstFire Option)
10.04 Securities Purchase Agreement dated October 29, 2020 (Geneva SPA)
10.05 Convertible Promissory Note dated October 29, 2020 (Geneva Note)
10.06 Securities Purchase Agreement dated November 25, 2020 (Geneva SPA)
10.07 Convertible Promissory Note dated November 25, 2020 (Geneva Note)
10.08 Securities Purchase Agreement dated September 14, 2020 (Blasiak SPA)
10.09 Convertible Promissory Note dated September 14, 2020 (Blasiak Note)
10.10 Option Agreement dated September 14, 2020 (Blasiak Option)
10.11 Securities Purchase Agreement dated September 14, 2020 (Bauman SPA)
10.12 Convertible Promissory Note dated September 14, 2020 (Bauman Note)
10.13 Option Agreement dated September 14, 2020 (Bauman Option)
10.14 Bauman Note Amendment dated October 31, 2020 (Bauman Note Amendment)
10.15 Bauman Option Amendment dated October 31, 2020 (Bauman Option Amendment)
10.16 Leonite Note Amendment dated July 12, 2020 (Leonite Note Amendment)
10.17 Leonite Series A Share Purchase Agreement dated July 12, 2020 (Leonite Series A)
10.18 Leonite Series B Share Purchase Agreement dated July 12, 2020 (Leonite Series B)
10.19 Leonite Warrant Agreement dated July 12, 2020 (Leonite Warrant)
10.20 Securities Purchase Agreement dated July 12, 2020 (Leonite SPA)
10.21 Convertible Promissory Note dated July 12, 2020 (Leonite Note)
10.22 Option Agreement dated July 12, 2020 (Leonite Option)
10.23 Leonite Option Amendment (Leonite Option Amendment)
10.24 Securities Purchase Agreement dated August 13, 2020 (Auctus SPA)
10.25 Convertible Promissory Note dated August 13, 2020 (Auctus Note)
10.26 Auctus Warrant Agreement dated August 13, 2020 (Auctus Warrant)
10.27 Labrys Term Sheet dated November 24, 2020 (Labrys Term Sheet)
10.28 Labrys Conversion Notice dated November 25, 2020 (Labrys Conversion)
10.29 Securities Purchase Agreement dated November 30, 2020 (Labrys SPA)
10.30 Convertible Promissory Note dated November 30, 2020 (Labrys Note)
10.31 Option Agreement dated November 30, 2020 (Labrys Warrants)